IP Library Patent Application 11659170
Patent Application
App. No. 11/659,170

Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/659,170
Abstract

Described herein is a microbial composition used to enhance anti-cancer drugs. Specifically, microbial compositions that comprise a part of or an entire microorganism having surface lectins specific to carbohydrate moieties on tumor surface combined with an oncolytic agent.

Claims (13)

1 . A therapeutic composition used to treat cancer, comprising a cytotoxic microorganism and one or more chemotherapeutic agent, wherein said cytotoxic microorganism has a lectin that binds to a carbohydrate moiety on the surface of a cancer cell, and wherein said composition synergistically inhibits tumor growth.

2 . The composition of claim 1 , wherein said chemotherapeutic agent is selected from the group consisting of aminoglutethimide, Amsacrine, Anastrozole, asparaginase, BCG, bicalutamide, Bleomycin, Buserelin, Busulfan, Capecitabine, carboplatin, Carmustine, chlorambucil, cisplatin, Cladribine, Clodronate, cyclophosphamide, cyproterone, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, diethylstilbestrol, Docetaxel, Doxorubicin, Epirubicin, Estramustine, etoposide, Exemestane, Filgrastim, Fludarabine, Fludrocortisone, fluorouracil, Fluoxymesterone, Flutamide, Gemcitabine, Goserelin, hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Interferon Alfa, Irinotecan, Letrozole, Leucovorin, Leuprolide, Levamisole, Lomustine, Mechlorethamine, Medroxyprogesterone, Megestrol, Melphalan, mercaptopurine, Mesna, methotrexate, mitomycin, Mitotane, Mitoxantrone, Nilutamide, Octreotide, Oxaliplatin, Paclitaxel, Pamidronate, Pentostatin, Plicamycin, Porfimer, procarbazine, Raltitrexed, Rituximab, streptozocin, Tamoxifen, Temozolomide, Teniposide, testosterone, thioguanine, Thiotepa, Topotecan, Trastuzumab, Tretinoin, Vinblastine, Vincristine, Vindesine, Vinorelbine and the like.

3 . The composition of claim 1 , wherein said cytotoxic microorganism is selected from the group consisting of clostridium, pertussis, diptheria, listeria , and the like.

4 . The composition of claim 1 , wherein said composition effectuates necrosis of cancer cells.

5 . A composition for the treatment of cancer, comprising an effective amount of a cytotoxic fixed microorganism capsules and a chemotherapeutic agent, wherein said composition effectuates a synergistic therapeutic effect.

6 . The composition of claim 5 , wherein said cytotoxic fixed microorganism has lectins that bind to carbohydrate moieties on the surface of cancer cells.

7 . The composition of claim 6 , wherein said carbohydrate moieties is galectin.

8 . The composition of claim 7 , wherein said galectin is galectin-3.

9 . The composition of claim 5 , wherein said composition effectuates tumor necrosis.

10 . A method of treating a subject suffering from cancer by administering an effective therapeutic amount of a composition comprising a cytotoxic microorganism and one or more chemotherapeutic agents.

11 . The method of claim 10 , wherein said chemotherapeutic agent is selected from the group consisting of aminoglutethimide, Amsacrine, Anastrozole, asparaginase, BCG, bicalutamide, Bleomycin, Buserelin, Busulfan, Capecitabine, carboplatin, Carmustine, chlorambucil, cisplatin, Cladribine, Clodronate, cyclophosphamide, cyproterone, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, diethylstilbestrol, Docetaxel, Doxorubicin, Epirubicin, Estramustine, etoposide, Exemestane, Filgrastim, Fludarabine, Fludrocortisone, fluorouracil, Fluoxymesterone, Flutamide, Gemcitabine, Goserelin, hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Interferon Alfa, Irinotecan, Letrozole, Leucovorin, Leuprolide, Levamisole, Lomustine, Mechlorethamine, Medroxyprogesterone, Megestrol, Melphalan, mercaptopurine, Mesna, methotrexate, mitomycin, Mitotane, Mitoxantrone, Nilutamide, Octreotide, Oxaliplatin, Paclitaxel, Pamidronate, Pentostatin, Plicamycin, Porfimer, procarbazine, Raltitrexed, Rituximab, streptozocin, Tamoxifen, Temozolomide, Teniposide, testosterone, thioguanine, Thiotepa, Topotecan, Trastuzumab, Tretinoin, Vinblastine, Vincristine, Vindesine, Vinorelbine and the like.

12 . The method of claim 10 , wherein the microorganism is attenuated.

13 . The method of claim 10 , wherein said microorganism is selected from the group consisting of clostridium, pertussis, diptheria, listeria , and the like.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 17, 2019
From: 10X FUND L.P.
To: GALECTIN THERAPEUTICS, INC.
Reel/Frame 050399/0679 →
SECURITY AGREEMENT Recorded Aug 26, 2009
From: PRO-PHARMACEUTICALS, INC.
To: 10X FUND, LP
Reel/Frame 023134/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2008
From: PLATT, DAVID; ZOMER, ELIEZER
To: PRO-PHARMACEUTICALS, INC.
Reel/Frame 022013/0673 →